ebook Munafa Stock Market Course + Intraday & FNO calls  

       

Akebia Therapeutics (AKBA) Technical (Analysis) Reports Akebia Therapeutics ["Technical Analysis"] Reports -NASDAQ Stock Exchange MunafaSutra.com

Complete & easy to understand technical analysis of Akebia Therapeutics (AKBA)

Technical Analysis Report for NASDAQ stock AKBA Akebia Therapeutics. Dated: 15 May 2026 Updated Daily. Stock trades under Health Care Deals in Major Pharmaceuticals in NASDAQ stock exchange

If you are looking for Tomorrow's Movement Predictions for NASDAQ stock AKBA Akebia Therapeutics then click here. or read Experts views on Akebia Therapeutics or Forecast & share price targets of Akebia Therapeutics

Akebia Therapeutics Opened at 1.13 and Closed at: 1.07, which is -6.54% of previous session's close. It moved within a range of 1.06 and 1.15
The session was a Bearish session with an average volume of 4020622, which is 13.46% of previous session's volumes.

  • The stock has fallen, and its short term trend is also negative and in a downtrend.
  • The stock has fallen, and its long term trend is also negative and in a downtrend.

A Dead cross was found 6 days back on mid term averages

Support for tomorrow is 1.02 and resistance for tomorrow is 1.11
These support and resistance points are valid for the first 5-15 minutes charts

Above are simple pivot point calculations. For a list of much stronger support and resistance levels click here. These are way more stronger support and resistance levels, and mark trend reversals and are Support & Resistance levels recommended by experts.

Support for tomorrow's hourly charts is 1.04, 1 resistance for tomorrow's hourly charts is 1.13, 1.18

10 Day SMA for Akebia Therapeutics (AKBA) is 1.25 and stock is trading below these levels. This is not a good sign for its short term trend

20 Day SMA for Akebia Therapeutics (AKBA) is 1.33 and the stock is trading below these levels. This is not a good sign for its mid term trend

50 Day SMA for Akebia Therapeutics (AKBA) is 1.38 and the stock is trading below these levels. This is not a good sign for its mid to long term trend

100 Day SMA is 1.39 and the stock is trading below these levels. This is not a good sign for its long term trend

200 Day SMA Akebia Therapeutics is 1.96 and stock is trading below these levels. This is not a good sign for its long term trend

20 DMA of Akebia Therapeutics is at 1.33 and 200 DMA is at 1.96, while 50 DMA and 100 DMA are at 1.38 and 1.39 respectively

Akebia Therapeutics (AKBA) moving average of 20 SMA is at 1.33 and 20 EMA is at 1.29

Akebia Therapeutics (AKBA) moving average of 50 SMA is at 1.38 and 50 EMA is at 1.36

Akebia Therapeutics (AKBA) moving average of 100 SMA is at 1.39 and 100 EMA is at 1.54

Akebia Therapeutics (AKBA) moving average of 200 SMA is at 1.96 and 200 EMA is at 1.72

Vtv Therapeutics has performed better than Akebia Therapeutics in short term. You could have earned much better returns by investing in Vtv Therapeutics, about 16.84% more returns!

Vistagen Therapeutics has performed better than Akebia Therapeutics in short term. You could have earned much better returns by investing in Vistagen Therapeutics, about 27.39% more returns!

Akebia Therapeutics has performed better than Sonoma Pharmaceuticals in short term. Holding Akebia Therapeutics could be a better choice for now!

Rhythm Pharmaceuticals has performed better than Akebia Therapeutics in short term. You could have earned much better returns by investing in Rhythm Pharmaceuticals, about 30.7% more returns!

Pacira Pharmaceuticals has performed better than Akebia Therapeutics in short term. You could have earned much better returns by investing in Pacira Pharmaceuticals, about 15.99% more returns!

Akebia Therapeutics has performed better than Phibro Animal in short term. Holding Akebia Therapeutics could be a better choice for now!

Oramed Pharmaceuticals has performed better than Akebia Therapeutics in short term. You could have earned much better returns by investing in Oramed Pharmaceuticals, about 44.63% more returns!

Opko Health has performed better than Akebia Therapeutics in short term. You could have earned much better returns by investing in Opko Health, about 14.27% more returns!

Intellia Therapeutics has performed better than Akebia Therapeutics in short term. You could have earned much better returns by investing in Intellia Therapeutics, about 13.33% more returns!

Angiodynamics Inc has performed better than Akebia Therapeutics in short term. You could have earned much better returns by investing in Angiodynamics Inc, about 24.58% more returns!

Ani Pharmaceuticals has performed better than Akebia Therapeutics in short term. You could have earned much better returns by investing in Ani Pharmaceuticals, about 21.7% more returns!

Eton Pharmaceuticals has performed better than Akebia Therapeutics in short term. You could have earned much better returns by investing in Eton Pharmaceuticals, about 52.66% more returns!

Galectin Therapeutics has performed better than Akebia Therapeutics in short term. You could have earned much better returns by investing in Galectin Therapeutics, about 19.29% more returns!

Guardant Health has performed better than Akebia Therapeutics in short term. You could have earned much better returns by investing in Guardant Health, about 29.11% more returns!

Akebia Therapeutics Technical analysis of indicators

Price action analysis of Akebia Therapeutics (AKBA) based on a short term time period is negative, but sellers have recently become active on the stock. This cannot be called a strong downtrend, specially if selected time duration is small

ADX buy sell signal for Akebia Therapeutics stock for short term is SELL. Signal strength is Weak and stock is losing momentum.

MACD generated a SELL signal for Akebia Therapeutics in short term and the sell signal is strong.

Akebia Therapeutics Stock is trading near its recent LOWS in short term which reflects strong selling momentum. Bears are getting stronger in this stock.

Ichimoku cloud is of red color and prices are below the red cloud Prices appear to be coming down

CCI has generated a SELL signal for Akebia Therapeutics in short term and SELL signal is strong!

RSI is generating a SELL signal in short term and selling is picking up momentum.

MRSI is in positive zone. This is a BUY zone

Although the stock is in the BUY zone, but buying might be slowing down

Stock of Akebia Therapeutics is picking up selling momentum according to indicator.

Volume based indicators are showing selling momentum.

Volume Weighted Averaged Price (VWAP) for short term is 1.22 and Akebia Therapeutics AKBA stock is trading below this level. This means that stock is falling with high volumes. VWAP is falling down

People seem to be coming out and selling the Akebia Therapeutics AKBA stock. Volume based technical analysis of Akebia Therapeutics AKBA stock is negative.

Akebia Therapeutics Stock has given negative returns over a short term period. Returns for a longer term period have been negative.

Force Index is moving in a negative zone, which indicates selling momentum for short term... Selling momentum is getting weaker.

Tomorrow's Predictions

You should also read Tomorrow's Movement Predictions for NASDAQ stock AKBA Akebia Therapeutics These predictions are based on various factors, are easy to understand, and upto 75% accurate!

And AKBA Experts View which covers a lot of information including buying and selling signals

AKBA future forecast & share price targets

You can also take a look at the Charts and indicator analysis here Announcements & NEWS by Akebia Therapeutics or View Candle Stick Charts here

Chart Akebia Therapeutics (AKBA)  Technical (Analysis) Reports Akebia Therapeutics [

Videos related to: Akebia Therapeutics (AKBA) Technical (Analysis) Reports Akebia Therapeutics ["Technical Analysis"] Reports -NASDAQ Stock Exchange MunafaSutra.com

Hindi Video Correct Way Of Technical Analysis How To Find Entry Exit Points On Charts

Hindi Video Most Important Stock Market Video. No Success Without This Formula

Akebia Therapeutics (AKBA)  Technical (Analysis) Reports Akebia Therapeutics [

 

Back to top